Scholar Rock (SRRK)
(Delayed Data from NSDQ)
$31.96 USD
+0.56 (1.78%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $31.95 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Scholar Rock Holding Corporation's return on equity, or ROE, is -127.11% compared to the ROE of the Medical - Biomedical and Genetics industry of -61.64%. While this shows that SRRK has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
SRRK 31.96 +0.56(1.78%)
Will SRRK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SRRK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRRK
Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross?
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
SRRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SRRK
Scholar Rock Holding (SRRK) Sees Price Target Revision by BMO Capital | SRRK Stock News
Decoding Scholar Rock Holding Corp (SRRK): A Strategic SWOT Insight
Q2 2025 Scholar Rock Holding Corp Earnings Call Transcript
SRRK Crosses Below Key Moving Average Level
Scholar Rock outlines Q3 2025 U.S. apitegromab launch plans amid regulatory progress and global expansion focus